Post by Staburo GmbH

From Clinical Question to Treatment Effect: A Practical Estimand Workshop Series Since the introduction of ICH E9(R1) in 2019, estimands have transformed the definition and interpretation of treatment effects in clinical trials. With ICH M11 now embedding estimand thinking into protocol development, estimands do more than provide a statistical framework. They connect the clinical question, study design, analysis strategy, and interpretation of results. How can organizations implement estimands effectively across the clinical development lifecycle? To help answer this question, our cross-functional team of medical writers Sam Hamilton and Alison McIntosh), data scientists (Hannes Buchner, Gabriele Bleckert) and transparency experts (Maarten van Dijk, PhD, Ulrike Fischer) developed a practical three-level workshop series. 🔹 Level 1 – The Big Picture Learn how estimands influence study design, timelines, resources, and budgets. Ideal for: Business development professionals, proposal teams, senior managers, and clinical operations leaders. Next workshop: 07 Jul 2026 🔹 Level 2 – Practical Utility Explore how clinicians, statisticians, medical writers, and transparency professionals integrate estimands into protocol development, reporting and disclosure. Ideal for: Medical writers, clinicians, transparency professionals, and disclosure managers. Next workshop: 08 Jul 2026 🔹 Level 3 – The Deep Dive Apply estimand principles to real-world examples, address intercurrent events, and evaluate their impact on trial analyses. Ideal for: Statisticians and data managers. Next workshop: 09-10 Jul 2026 👉 Swipe the carousel to learn more. Visit the Staburo Academy  website and search for “Estimand workshop” for further details. 📩 Interested in one or more of these workshops. Send us a direct message. #ClinicalDevelopment #ClinicalResearch #Estimands #ICHE9 #ICHM11 #MedicalWriting #Biostatistics #ClinicalTrials #DrugDevelopment #RegulatoryScience #Biotech #ClinicalOperations #ProtocolDevelopment #Transparency #Disclosure